ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2022
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Assessing the methodologic heterogeneity of Canadian Urological Association guidelines Adoption of the GRADE approach (2018-2023).Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review.The oncologist · 2025Review
- Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences.Current oncology (Toronto, Ont.) · 2025Article
- Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.Future oncology (London, England) · 2025Review
- Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada.Future oncology (London, England) · 2025Article
- Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- 2023 Canadian Urological Association/Pediatric Urologists of Canada guideline: Pediatric patients with neurogenic lower urinary tract dysfunction Full-text version.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.Targeted oncology · 2023Review
- A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS).Current oncology (Toronto, Ont.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.